FDA warns of heart-re­lat­ed events, can­cer, blood clots, and death for JAK in­hibitors

The FDA on Wednes­day wrapped up its long-await­ed re­view of Pfiz­er’s large, ran­dom­ized tri­al eval­u­at­ing the safe­ty of its JAK in­hibitors Xel­janz and Xel­janz XR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.